Researchers want to learn more about the day-to-day use of Iberogast in people who have functional and motility-related gastrointestinal (stomach and bowel) diseases. Functional and motility-related stomach and bowel diseases are conditions in which the functionality of the gut, mainly the gut muscles or the gut/brain axis is disturbed. Functional and motility related stomach and bowel diseases cause symptoms like heartburn, cramps and u pain of the upper and middle part of the belly, also known as functional dyspepsia (FD), and irritable bowel syndrome (IBS). IBS affects predominantly the lower digestive system and causes symptoms like pain of the belly, cramps, bloating, diarrhea, and constipation. In this study, the researchers want to learn more about Iberogast, a plant-based treatment. Iberogast is available to treat stomach and bowel diseases such as FD and IBS. Earlier studies with Iberogast have shown how well it works and how it affects the body. But, little is known about the day-to-day use of Iberogast and how satisfied patients are who take it. So in this study, the researchers want to learn more about Iberogast including: * how well it works in day-to-day use * how it affects the body, also referred to as tolerability * how it is used day-to-day * how safe it is * how satisfied patients are who take it To answer these questions, the researchers will collect information from pharmacies in Germany. Patients who get Iberogast from these pharmacies to help treat their gastrointestinal disease will complete a questionnaire before, during and after taking Iberogast. The researchers will use the results from the questionnaires to learn more about: * the disease details of the patients who are taking Iberogast * the patients' symptoms while taking Iberogast * if the patients' symptoms change after taking Iberogast * how satisfied patients are with Iberogast * if the patients had adverse events An adverse event is any medical problem that a participant has during a study. This study will include patients in Germany who: * have functional stomach and bowel symptoms or disorders like FD or IBS * take Iberogast to treat symptoms of their stomach and bowel disease * are able to complete the questionnaire There will be no required tests or visits with a study doctor in this study. No treatments will be given as part of this study. The researchers will review information collected from patients who have decided for their own or by recommendation of their doctors or pharmacist to take Iberogast. The researchers will collect the results from the patient questionnaires from November 2017 to March 2018.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Onset of symptom improvement as assessed by patients
Timeframe: At baseline
Symptom improvement as assessed by patients.
Timeframe: 7 days
Effectiveness of Iberogast in comparison to other treatments as assessed by patient.
Timeframe: 7 days
Number of participants with gastrointestinal complaints ,categorized by severity.
Timeframe: 7 days
Patients´ usage behavior as assessed by patients.
Timeframe: At baseline
Number of participants with adverse events.
Timeframe: 7 days
Patients 'satisfaction as assessed by patients.
Timeframe: 7 days